Healthcare Pharmaceuticals Ltd (HPL) and Eli Lilly and Company today announced the launch of Trulicity (dulaglutide) in Bangladesh. This is the first once-a-week use, injectable medication designed to improve blood sugar control in adults with type 2 diabetes, according to a press release issued to media.
The drug comes in an easy to use, single-dose pen that does not require mixing or measuring and can be administered at any time of the day, independent of meals.
As Type 2 diabetes is a progressive disease and in Bangladesh many patients do not meet their treatment goals. It is hoped that this new, non-insulin, injectable will better meet patients’ needs and convenience.
Advocacy Action: What policies are in place to ensure pharmaceutical research in your country is translated into affordable medicines for the population?